Table 2.
The network meta-analysis results of PET/CT with different tracers to detect bone metastasis in PCa.
| Test | Absolute Sensitivity | Absolute Specificity | Diagnostic OR [Rank] | SuperiorityIndex [Rank] | Relative Sensitivity | Relative Specificity | Datasets, n | Studies, n | |
|---|---|---|---|---|---|---|---|---|---|
| 18F-NaF | 0.95 (0.91–0.99) |
0.88 (0.83–0.93) |
248.15 (34.14–799.75) [2] |
3.33 (0.20–9.00) [2] |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
10 | 9 | |
| 18F-Choline | 0.89 (0.85–0.93) |
0.91 (0.86–0.96) |
123.18 (21.09–361.86) [4] |
1.71 (0.14–7.00) [4] |
0.94 (0.88–1.00) |
1.03 (0.95–1.11) |
7 | 7 | |
| 11C-Choline | 0.86 (0.81–0.91) |
0.94 (0.89–0.99) |
208.88 (21.37–780.88) [3] |
1.92 (0.14–7.00) [3] |
0.91 (0.84–0.98) |
1.07 (0.98–1.16) |
7 | 7 | |
| 68Ga-PSMA | 0.91 (0.83–0.99) |
0.99 (0.94–1.04) |
3379817.37 (49.99–5941029.19) [1] |
7.30 (0.60–11.00) [1] |
0.96 (0.87–1.05) |
1.12 (1.04–1.20) |
5 | 5 | |
| 18F-FDG | 0.69 (0.54–0.84) |
0.85 (0.70–1.00) |
81.17 (1.35–497.30) [6] |
0.49 (0.09–3.00) [6] |
0.73 (0.57–0.89) |
0.96 (0.78–1.14) |
3 | 3 | |
| 18F-FACBC | 0.80 (0.62–0.98) |
0.59 (0.37–0.81) |
92.40 (0.40–598.84) [5] |
0.55 (0.09–3.00) [5] |
0.84 (0.65–1.03) |
0.67 (0.42–0.92) |
2 | 2 | |
Data are reported as mean (range) unless otherwise indicated.
PET/CT, positron emission tomography/computed tomography; PCa, prostate cancer; NaF, sodium fluoride; PSMA, prostate membrane antigen; FDG, fludeoxyglucose; FACBC, fluciclovine; CI, credible interval; OR, odds ratio.